The discovery and subsequent introduction of dantrolene in 1979 was a major breakthrough in the treatment of malignant hyperthermia (MH) that is responsible for saving hundreds, if not thousands, of lives. However, one of the major challenges in the successful treatment of MH is the need for rapid mixing, suspension, and administration of dantrolene during a crisis.
Ryanodex® (Eagle Pharmaceuticals) is a new FDA approved preparation of dantrolene significantly speeds dantrolene preparation and administration. With Ryanodex, 250 mg of dantrolene can be suspended in 5 ml of sterile water for injection in less than 30 seconds and administered in less than one minute. Thus, an initial treatment dose of dantrolene of 2.5mg/kg for an 80 kg patient requires only 4 ml (200 mg) of Ryanodex.
Although efficacy of Ryanodex in treating MH in an established pig model has been demonstrated,1 the preparation has not yet been used to treat MH in humans. Now that FDA approval for the treatment of MH by Ryanodex has been granted, MHAUS recommends that The North American Malignant Hyperthermia Registry AMRA Report be utilized to report Ryanodex use. This will permit independent evaluation of its safety and efficacy in the treatment of human MH.
The above story is based on materials provided by Malignant Hyperthermia Association of the United States (MHAUS). Note: Materials may be edited for content and length.
Cite This Page: